OGN Organon & Co.

13.91USD-0.07%Mkt Cap: 3.65B USDP/E: 17.83

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, …

Institutional holders20 on file

Key Statistics

Company
Market Cap3.65B USD
Enterprise Value10.75B USD
Revenue (TTM)6.10B USD
Gross Profit3.31B USD
Net Income (TTM)187.00M USD
Revenue/Share23.33 USD
Last Price13.91 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees10.0K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISIN—
Valuation
P/E (Trailing)17.83
P/E (Forward)3.81
PEG—
EV/EBITDA6.94
EV/Revenue1.76
P/S0.60
P/B3.06
EPS (TTM)0.78 USD
EPS (Forward)3.65 USD
52W Range
5.690100% of range13.94
52W High13.94 USD
52W Low5.690 USD
Profitability
Gross Margin53.30%
Oper. Margin19.76%
EBITDA Margin25.40%
Profit Margin3.01%
ROE24.87%
ROA1.45%
ROIC6.95%
ROCE11.70%
Growth
Revenue Growth-1.70%
Earnings Growth-1.60%
Cash Flow & Leverage
Operating CF700.00M USD
CapEx (TTM)316.00M USD
FCF Margin11.83%
FCF Yield19.75%
Net Debt7.10B USD
Net Debt/EBITDA4.58
Net Debt/FCF9.84
Balance Sheet
Debt/Equity11.49
Current Ratio2.02
Quick Ratio1.11
Book Value/Sh4.54 USD
Cash/Share5.54 USD
Dividends
Fwd Div Rate0.08 USD
Trail. Div Rate0.08 USD
Div. Yield0.57%
5Y Avg Yield2.43%
Payout Ratio10.26%
Ex-Div DateNov 9, 2026
Pay DateDec 10, 2026
Analyst Consensus
Rating—
Target (Mean)10.33 USD
Upside (mean)-25.7%
Target Range8.000 USD – 14.00 USD
8.000-25.7% to mean14.00
# Analysts3
Ownership
Shares Out.262.62M
Float243.05M
Insiders0.46%
Institutions86.78%
Short Interest
Short Ratio8.8d
Short % Float8.52%
Short % Out.7.50%
Shares Short19.69M
Short (prev mo.)18.96M
Technical
SMA 5013.76 (+1.1%)
SMA 20011.78 (+18.1%)
Beta1.49
S&P 52W Chg12.08%
Avg Vol (30d)2.68M
Avg Vol (10d)3.17M
Technical Indicators
RSI (14)65.7
MACD0.0418
MACD Signal0.0378
MACD Hist.+0.0040
BB Upper13.96 USD
BB Middle13.84 USD
BB Lower13.73 USD
BB Width1.69%
ATR (14)0.0392 USD
Vol Ratio (20d)1.22x

About Organon & (NYSE: OGN)

›

Organon & (NYSE: OGN) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 10,000 employees.

The shares were at 13.91 USD on 19 November 2026, up 86.0% over 52 weeks. Its 52-week range is 5.690 USD to 13.94 USD, and it trades at the top of that range.

At a market capitalisation of 3.65B USD, it trades at 17.8 times trailing earnings and 3.8 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 26.0, a discount of 32% for OGN. It pays a dividend yielding 0.57% (it pays out 10% of its earnings), against a median of 2.43% among the dividend payers in that peer group.

Organon & reports return on equity of 24.9%, an operating margin of 19.8% and revenue down 1.7% year over year.

Its debt exceeds its cash by 7.10B USD, a debt-to-equity ratio of 11.49. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 3 analysts cover the stock; their mean price target of 10.33 USD is 25.7% below the current price. The next earnings report is expected on 11 February 2027.